Inactive Instrument

All News Allon Therapeutics Inc. Toronto S.E.

Equities

NPC

CA0197741089

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

Paladin Labs Inc. completed the acquisition of substantially all assets from Allon Therapeutics, Inc..	13-07-16	CI
Paladin Labs Inc. signed a non-binding term sheet to acquire substantially all assets from Allon Therapeutics, Inc. for CAD 0.9 million.	13-05-30	CI
Allon Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2013	13-04-29	CI
Allon Therapeutics, Inc. Reports Earnings Results for the Year Ended December 31, 2012	13-03-27	CI
Allon Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	13-03-27	CI
Allon Updates On Strategic Review Process	13-02-05	CI
Michael Aldridge Resigns as Director of Allon Therapeutics, Inc	13-01-30	CI
Allon Therapeutics, Inc. Implements Staff and Administrative Reductions; Announces Resignation of Michael Gold as Vice President, Clinical Development and Chief Medical Officer	12-12-21	CI
Allon Therapeutics, Inc. Announces PSP Clinical Trial Results; Announces to Reduce Staff	12-12-18	CI
The United States, New Zealand & Mexico Issue Patent for New Allon Therapeutics, Inc. Platform	12-12-05	CI
Allon Therapeutics, Inc. Completes Patient Treatment in Pivotal Trial Evaluating Allon's Davunetide	12-11-13	CI
Allon Therapeutics, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2012	12-11-05	CI
Allon Therapeutics, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2012	12-08-07	CI
Allon Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2012	12-05-08	CI
Allon Therapeutics, Inc. announced that it expects to receive CAD 10 million in funding from NDI Capital and other investors.	12-04-16	CI
Allon Therapeutics, Inc. Receives U.S. Patent for Neurotoxicity Technology Platform in the Treatment of Peripheral Neuropathy	12-03-28	CI
Allon Therapeutics, Inc. Advances Parkinson's Disease Program	12-03-12	CI
Allon Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	12-03-09	CI
Allon Therapeutics, Inc. Reports Audited Earnings Results for the Year Ended December 31, 2011	12-03-09	CI
Allon Therapeutics, Inc. announced that it has receive CAD 2.5 million in funding from NDI Capital.	12-03-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Allon Therapeutics Inc. Toronto S.E.

Equities

NPC

CA0197741089

All News

Filters